

PRESIDENTS



CLAUDIO CERCHIONE
ISTITUTO SCIENTIFICO
ROMAGNOLO PER LO
STUDIO DEI TUMORI
DINO AMADORI - IRCCS
ITALY



DAVID W. GREENING
BAKER HEART AND
DIABETES INSTITUTE
LA TROBE UNIVERSITY
AUSTRALIA



GIOVANNI MARTINELLI
ISTITUTO SCIENTIFICO
ROMAGNOLO PER LO
STUDIO DEI TUMORI
DINO AMADORI - IRCCS
ITALY



ANTONIA REALE
MONASH UNIVERSITY
THE ALFRED
AUSTRALIA



ANDREW SPENCER
MONASH UNIVERSITY
THE ALFRED
AUSTRALIA



ANGELO VACCA
UNIVERSITÀ DEGLI STUDI
DI BARI ALDO MORO
ITALY

SCIENTIFIC BOARD

C. CERCHIONE R. RIA
D. W. GREENING A. SPENCER
G. MARTINELLI A. VACCA
A. REALE

SCIENTIFIC SECRETARIAT

C. CERCHIONE A. REALE
D. W. GREENING G. SIMONETTI
A. FRASSANITO A. G. SOLIMANDO
G. MARTINELLI A. SPANCER
A. MELACCIO A. VACCA



PATRONAGE

ISTITUTO
ROMAGNOLO
PER LO STUDIO
DEI TUMORI
DINO AMADORI

SERVIZIO SANITARIO REGIONALE
EMILIA-ROMAGNA
Azienda Unità Sanitaria Locale della Romagna



SIE
Società Italiana
di Ematologia



SIMI
SOCIETÀ ITALIANA
DI MEDICINA INTERNA
Patrocina

AlfredHealth



IN ASSOCIATION WITH
soho
SOCIETY OF HEMATOLOGIC ONCOLOGY

ORGANIZING SECRETARIAT
Proeventi
info@proeventi.it
www.proeventi.it

1ST JULY 2021

EXTRACELLULAR VESICLES AND THEIR ROLE IN PATIENTS WITH MULTIPLE MYELOMA

10,5 CME/ECM FOR: PHYSICIANS, BIOLOGISTS, BIOMEDICAL
LABORATORY TECHNICIANS, NURSES

FREE
REGISTRATION

SOHOITALY.IT

@SOHOITALY



IN THE PAST DECADE, THERE HAVE BEEN MAJOR ADVANCES IN THE TREATMENT OF THE BLOOD CANCER MULTIPLE MYELOMA (MM). THE INTRODUCTION OF NOVEL AGENTS SUCH AS IMMUNE-MODIFYING AGENTS (IMiDs), PROTEASOME INHIBITORS, MONOCLONAL ANTIBODIES, WITH OR WITHOUT STEM CELL TRANSPLANTATION, HAS RESULTED IN SIGNIFICANTLY IMPROVED PATIENT SURVIVAL. MEANWHILE, THE INCREASED UNDERSTANDING OF MM TUMOR BIOLOGY HAS PROVIDED A RATIONALE FOR NEW COMBINATIONS OF DRUGS AND RISK-ADAPTED AND INDIVIDUALIZED TREATMENTS TO FURTHER IMPROVE PATIENT MANAGEMENT.

EXTRACELLULAR VESICLES (EVs) ARE CELL-DERIVED MEMBRANOUS PARTICLES THAT MEDIATE CELL-TO-CELL COMMUNICATION BY TRANSFERRING PROTEINS, LIPIDS AND NUCLEIC ACIDS LOCALLY AND THROUGH SYSTEMIC CIRCULATION. EVs ARE ACTIVE REGULATORS IN THE CROSS-TALK BETWEEN MM TUMOUR CELLS AND BONE MARROW MICROENVIRONMENT, WITH THE CAPACITY TO ALTER ANGIOGENESIS, OSTEOCLAST DIFFERENTIATION AND IMMUNOSUPPRESSION, PROMOTING TUMOUR PROGRESSION AND DRUG RESISTANCE. CIRCULATING EVs CONTAINING TUMOUR-SPECIFIC MOLECULAR SIGNATURES (ONCOPROTEINS, RNAs, DNA FRAGMENTS) HAVE POTENTIAL CLINICAL UTILITY AS NEXT-GENERATION LIQUID BIOPSY BIOMARKERS IN CANCER DIAGNOSIS AND MANAGEMENT, WITH THE POTENTIAL TO CHARACTERISE BOTH SPATIAL HETEROGENEITY AND CLONAL EVOLUTION THUS INFORMING NEW MODALITIES FOR DIAGNOSIS, RISK STRATIFICATION, MONITORING AND THERAPEUTIC INTERVENTION IN MM. HOWEVER, THE NANO-SCALE NATURE OF EVs AND THE COMPLEXITY OF BIOFLUIDS PRESENT CHALLENGES THAT NEED TO BE ADDRESSED BEFORE THE POTENTIAL OF EVs AS BIOMARKERS AND THERAPEUTIC TARGETS CAN BE ACHIEVED.

THE ITALIAN SOCIETY OF HEMATOLOGIC ONCOLOGY (SOHO ITALY) WAS ESTABLISHED AS A NON-PROFIT ORGANIZATION IN 2019 TO PROMOTE WORLDWIDE RESEARCH (EDUCATION, PREVENTION, PRECLINICAL AND CLINICAL STUDIES AND PATIENT CARE) OF HEMATOLOGIC MALIGNANCIES AND RELATED DISORDERS. IN THIS SCENARIO, SOHO ITALY TOGETHER WITH AUSTRALIAN COLLEAGUES AIM TO BRING TOGETHER INTERNATIONAL EXPERTS TO DISCUSS THE LATEST ADVANCES IN THE PATHOPHYSIOLOGY AND THERAPY OF MM AND TO BETTER UNDERSTAND THE ROLE OF EVs IN PATIENTS WITH MM.



CENTRAL EUROPEAN SUMMER TIME

07.50 OPENING REMARKS

C. CERCHIONE D. W. GREENING G. MARTINELLI A. REALE A. SPENCER A. VACCA

SESSION 1 - THE MULTIPLE MYELOMAS

H. EINSELE A. SPENCER G. MARTINELLI

08.00 WHAT IS SOHO ITALY **C. CERCHIONE G. MARTINELLI**

08.20 THE MULTIPLE MYELOMAS - BIOLOGY, DIAGNOSIS, RISK STRATIFICATION **J.L. HAROUSSEAU**

08.40 ROLE OF MICROENVIRONMENT IN MM **A. VACCA**

09.00 IMMUNE SYSTEM IN MM **P. NERI**

09.20 ABSTRACT SUBMISSION

09.30 LECTURE LIQUID BIOPSY IN MM **A. SPENCER**

BREAK

SESSION 2 - UNDERSTANDING EXTRACELLULAR VESICLES

M. BEBAWY A. VACCA D. W. GREENING

10.20 EXTRACELLULAR VESICLES - OVERVIEW, UPDATE **K. WITWER**

10.40 EXTRACELLULAR VESICLES IN CANCER—IMPLICATIONS FOR FUTURE IMPROVEMENTS IN CANCER CARE **A. RAI**

11.00 EVS AS CANCER DIAGNOSTICS **A. MÖLLER**

11.20 EV BYSTANDER SIGNALING AND CANCER RESISTANCE **P. SAMUEL**

11.40 TOOLS FOR TRACKING BIODISTRIBUTION OF CANCER EVS **B. SUNG**

12.00 ABSTRACT SUBMISSION

12.10 STUDENT/ECR NETWORK ON EVS (SNEV), OVERVIEW **A. NASIRI KENARI**

LUNCH

SESSION 3 - HOW I MANAGE MULTIPLE MYELOMA

K.C. ANDERSON C. CERCHIONE M.V. MATEOS

12.55 HOW I MANAGE FRONTLINE MM **M. V. MATEOS**

13.15 HOW I MANAGE RELAPSED/REFRACTORY MM **C. CERCHIONE**

13.35 BIOLOGICALLY BASED THERAPIES FOR MM **K.C. ANDERSON**

13.55 NEW TREATMENT AVENUES IN MM **H.C. LEE**

14.15 MANAGING INFECTIONS IN MM **R. RIA**

14.35 ABSTRACT SUBMISSION

BREAK

SESSION 4 - ROLE OF EXTRACELLULAR VESICLES IN MYELOMA

A. REALE G. SIMONETTI B. SUNG

14.55 EVS IN MM BONE DISEASE **K. VANDERKERKEN**

15.15 EVS IN MM PROGRESSION **A. ROCCARO**

15.35 MM FIBROBLASTS ENHANCE BONE MARROW ANGIOGENESIS VIA SMALL EVS RELEASE **I. SALTARELLA**

15.55 MM-SMALL EVS, OMICS, PLASMA **A. REALE**

16.15 ABSTRACT SUBMISSION

16.25 LECTURE PROTEOMIC INSIGHTS IN EVS: KEY PLAYERS IN CANCER AND POTENTIAL THERAPEUTIC STRATEGY **D. W. GREENING**

16.55 CONCLUDING REMARKS C. CERCHIONE G. MARTINELLI A. VACCA

SUPPORTED BY AN UNRESTRICTED EDUCATIONAL GRANT FROM

